Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tivic Health Systems ( (TIVC) ).
On August 20, 2025, Tivic Health Systems announced the acquisition of two investigational new drug applications for Entolimod from Statera Biopharma. These applications cover the treatment of acute radiation syndrome and advanced cancers, allowing Tivic to engage with the FDA on regulatory pathways and initiate clinical trials in related conditions. This strategic move enhances Tivic’s position in the immunotherapeutics industry by advancing Entolimod’s development and exploring its potential as an anti-tumor agent.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified immunotherapeutics company that utilizes a dual platform strategy involving biopharmaceutical and bioelectronic systems to address unmet medical needs by targeting the immune system. The company focuses on biologics compounds that activate innate immune pathways to prevent cell death in bone marrow and epithelial tissues affected by radiation and age. Tivic’s lead drug candidate, Entolimod, is a TLR5 agonist in late-stage development for acute radiation syndrome, which has received Fast Track designation.
Average Trading Volume: 759,734
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
For a thorough assessment of TIVC stock, go to TipRanks’ Stock Analysis page.